Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to define subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)-mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying highgrade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.
Introduction
Glioblastoma, which is pathologically the most aggressive form, has a median survival range of only 9-15 months (Karpeh et al., 2001; Stewart, 2002; Stupp et al., 2005) . Advances in the basic knowledge of cancer biology and surgical techniques, chemotherapy and radiotherapy have led to little improvement in the survival rates of patients suffering from glioblastoma (Stewart, 2002) . Poor prognosis is attributable to difficulties of early detection, and to a high recurrence rate during post-initial treatment observation periods. Therefore, it is important to devise more effective therapeutic approaches, to reveal more clearly the biological features of glioblastoma, and identify novel target molecules for diagnosis and therapy of the disease. Several histological grading schemes exist, but the two-tiered World Health Organization (WHO) system is currently the most widely used (Kleihues and Cavenee, 2000) . A high WHO grade correlates with clinical progression and decreased survival. However, there are still many individual variabilities within diagnostic categories, leading to the need for developing additional prognostic markers. As prognostic markers are based on morphology, identification of new treatment strategies is limited. Identification of distinct molecular pathways has become critical for developing molecular targeted therapies.
Recently, developed microarray technology has permitted development of multi-organ cancer classification including gliomas (Ramaswamy et al., 2001; Rickman et al., 2001; Kim et al., 2002; Hunter et al., 2003; Mischel et al., 2004) , identification of tumor subclasses (Khan et al., 2001; Mischel et al., 2003; Shai et al., 2003; Sorlie et al., 2003; Liang et al., 2005; Nigro et al., 2005; Wong et al., 2005) , discovery of progression markers (Sallinen et al., 2000; Agrawal et al., 2002; van de Boom et al., 2003; Godard et al., 2003; Hoelzinger et al., 2005; Rich et al., 2005; Somasundaram et al., 2005) and prediction of disease outcomes (van't Veer et al., 2002; van de Vijver et al., 2002; Nutt et al., 2003; Freije et al., 2004) . Unlike clinicopathological staging, molecular staging can predict long-term outcomes of any individual based on gene expression profile of the tumor at diagnosis. Analysis of expression profiles of genes in clinical materials is an essential step toward clarifying the detailed mechanisms of oncogenesis and discovering target molecules for the development of novel therapeutic drugs.
The human 1 cDNA microarray (Agilent Technologies, Palo Alto, CA, USA) contains 12 811 clones from more than 7000 UniGene clusters. Each clone is represented by a PCR-amplified, double-stranded complementary DNA (cDNA) product, immobilized on the slide. mRNAs obtained from two biological samples were separately converted to cDNA labeled with distinct fluorescent dyes, usually cyanines 3 (Cy3) and 5 (Cy5), mixed together and hybridized to a single array. Hybridization intensities from the two dyes were measured, and compared for each gene within the array, to identify gene expression differences between the two samples. Utilization of a common reference sample for each array allowed objective comparisons between samples on separate arrays. In the present study, we used agilent cDNA microarrays to define expression patterns to distinguish between short-term and longterm survival of malignant gliomas.
Results

High-grade gliomas in this study
Patients initially showed histologically proven glioblastoma (grade IV), anaplastic astrocytoma or other malignant gliomas (grade III) corresponding to the WHO criteria. Seven patients with grade III and 22 patients with grade IV were included in this study (Table 1) . Univariate analysis of clinical features was performed against pathological diagnoses, age, gender and performance status (PS) with respect to survival. Pathological diagnoses, age and gender were not independent predictors of survival (Table 2) . Once all gliomas were sorted according to PS, significant difference was found between survival of patients with PS 0-60 and patients with PS 70-100 in our cases (Table 2) .
Identification of prognosis-related genes
We performed the univariate proportional hazard model to identify a set of genes that better correlated with censored survival time. Genes were selected if their P-value was less than 0.005 and the P-value was then used in a multivariate permutation test. We identified 21 genes whose expression was most strongly and consistently related to survival. These genes are listed in Table 3 , and include several genes that we believe to be biologically active such as DDR1 (discoidin domain receptor family, member 1) and KSP37 (Ksp37 protein) (see Discussion).
Relationships between results obtained by microarray analysis and by real-time PCR We chose 10 genes that were not previously associated with gliomas, to measure their mRNA levels by realtime quantitative reverse transcription-PCR. From 29 microarray-measured tumor samples, total RNAs from 27 tumor samples (14 long-term survivors and 13 shortterm survivors) were analysed for expressions of ALCAM (activated leukocyte cell adhesion molecule), DDR1, DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3), ITGA5 (integrin alpha 5), ITGB2 (integrin beta 2), KSP37, LDHC (lactate dehydrogenase C), LOC (hypothetical protein III  80  263  2  Anaplastic oligodendroglioma 60, M  III  90  294  3  Anaplastic oligodendroglioma 72, M  III  90  305  4  Anaplastic astrocytoma  32, M  III  100  545  5  Anaplastic astrocytoma  73, M  III  70  617  6  Anaplastic astrocytoma  45, M  III  60  698  7  Anaplastic astrocytoma  65, M  III  90  762  8  Glioblastoma  18, F  IV  60  111  9  Glioblastoma  64, F  IV  50  154  10  Glioblastoma  28, M  IV  70  202  11  Glioblastoma  45, M  IV  60  261  12  Glioblastoma  54, M  IV  40  268  13  Glioblastoma  68, M  IV  80  286  14  Glioblastoma  62, M  IV  70  347  15  Glioblastoma  80, M  IV  80  349  16  Glioblastoma  78, F  IV  60  350  17  Glioblastoma  69, M  IV  90  352  18  Glioblastoma  67, M  IV  50  396  19  Glioblastoma  63, M  IV  60 Table 3 . groups: positive and negative groups according to immunostaining score. Positive staining for DDR1 was confirmed to be associated with unfavorable overall survival time (P ¼ 0.043; Figure 1a ). Next, in new independent 19 glioma samples, similar results were obtained (P ¼ 0.049; Figure 1b ). Although our results were based on relatively small sample size, the correlation between DDR expression and survival was confirmed by real-time quantitative PCR and also confirmed immunohistochemical analysis in independent samples.
Glioma cell proliferation and invasion are inhibited by DDR1 siRNA DDR1 overexpression was linked to aggressiveness of glioma in our analysis. In order to determine whether downregulation of endogenous DDR1 suppresses proliferation and invasive behavior of gliomas, we synthesized short interfering RNA (siRNAs) against DDR1 mRNA to reduce expression of DDR1 protein. We analysed efficacy of siRNA-mediated inhibition of DDR1 mRNA synthesis in U251, GI-1, and T98G cells by real-time PCR. As shown in Figure 2a , when U251 cells were transfected with siRNAs against DDR-1 (DDR1-#1 and DDR1-#2), DDR1 mRNA was downregulated 48 h later (Po0.01), whereas transfection with a related control siRNA failed to modify DDR1 mRNA expression. When GI-1 and T98G cells were transfected with siRNAs against DDR-1 (DDR1-#1 and DDR1-#2), DDR1 mRNA was downregulated by 10-15% of control siRNA (Po0.01).
After transfection with siRNAs against DDR-1, U251 cell counts within 48 h were approximately 40-60% of untreated or control-siRNA-treated cells during this same period of time (Po0.01; Figure 2b ). GI-1 and T98G cell counts within 48 h were approximately 35-50% of untreated or control-siRNA-treated cells during this same period of time (Po0.01). Cell proliferation was significantly suppressed by siRNA against DDR1, as reflected in reduction of mRNA expression.
For invasion assays, transfectants were seeded onto Matrigel-coated invasion chambers, incubated for 24 h and total numbers of cells on the underside of each filter were determined. As shown in Figure 2c , transfections of U251 cells with anti-DDR1 siRNA inhibited cell invasion through the Matrigel by more than 80%, whereas the use of control siRNA had no effect (Po0.01). Transfections of GI-1 and T98G cells with anti-DDR1 siRNA inhibited cell invasion through the Matrigel by more than 70-80%, whereas the use of control siRNA had no effect (Po0.01). Therefore, invasion by cells was significantly suppressed by siRNA against DDR1, as reflected by reduced mRNA expression.
Discussion
Several works (Sallinen et al., 2000; Khan et al., 2001; Ramaswamy et al., 2001; Rickman et al., 2001; Agrawal et al., 2002; Kim et al., 2002; Veer et al., 2002; Vijver et al., 2002; Boom et al., 2003; Godard et al., 2003; Hunter et al., 2003; Mischel et al., 2003; Nutt et al., 2003; Shai et al., 2003; Sorlie et al., 2003; Freije et al., 2004; Mischel et al., 2004; Hoelzinger et al., 2005; Liang et al., 2005; Nigro et al., 2005; Rich et al., 2005; Somasundaram et al, 2005; Wong et al., 2005) showed the usefulness of utilizing methods of analysis of multiple forms of data including both clinical and multiple genes, to achieve a more precise discrimination of outcomes for individual patients. The same logical use of multiple forms of data and methods of analysis has been applied in the present study to accurately achieve better classification and prediction of glioma patients. In the present study, we used expression arrays to identify genes that reflect patient's survival. The groups of patients used represented the two extremes of glioma with respect to outcomes. Nutt et al. (2003) and Freije et al. (2004) together suggested that clinical differences in outcomes were reflected in global patterns of gene expression that could be appreciated using microarrays. Some of the genes that were critical components of patterns that were used to discriminate between longterm and short-term survivors are known to affect virulence of the malignant phenotype. Several groups have confirmed prognostic markers of glioma such as Insulin-like growth factor-binding protein 2 (IGFBP2) (Kim et al., 2002; Godard et al., 2003) , vascular endothelial growrh factor (VEGF) (Godard et al., 2003) , Osteonectin, Doublecortex, Semaphorin 3B (Rich et al., 2005 ) and brain-type fatty acid-binding protein (FABP7) (Liang et al., 2005) .
We have selected DDR1, KSP37 and DYRK3 from a 21-gene model (21 genes derived from multivariate analysis) to classify cases into unfavorable and favorable groups that exhibited significantly different survivals. We observed that glioma cell proliferation and invasion were significantly suppressed by siRNA against DDR1. The DDR1 is a tyrosine receptor kinase activated by various types of collagen, and is involved in cell-matrix communication (Vogel, 1999) . DDR1 is activated independently of b1 integrin (Vogel et al., 2000) . DDR1-collagen interaction facilitates the adhesion, migration, differentiation/maturation and cytokine/ chemokine production of leukocytes (Yoshimura et al., 2005) . DDR1 is overexpressed in several tumors including high-grade brain, esophageal and breast cancers (Weiner and Zagzag, 2000) . Based on our data and Ram et al. (2005) , DDR1 may play a potential role in proliferation and invasion of gliomas. Invasive phenotype is caused by activation of matrix metalloproteinase-2 in DDR1-overexpressing cells (Ram et al., 2006) . Glioma cell adhesion, including intercellular and 
Control
Negative control DDR1-1 DDR1-2 Figure 2 Effects of DDR1 knockdown by RNA interference on proliferation and invasiveness of human glioma cell lines. U251 cells were transiently transfected with short interfering RNAs (siRNA) and subjected to semiquantitative PCR analysis, proliferation assay or Matrigel invasion assays. (a) Reduction of DDR1 mRNA expression by siRNAs against DDR1 was determined by semiquantitative PCR analysis. Transfection with DDR1 siRNAs significantly reduced DDR1, whereas transfection with siRNAs targeted to an unrelated mRNA had no effect on DDR1 expression. *Po0.01 compared with both control groups. (b) Cell proliferation assay. Cells were cultured in 96-well plates in 100 ml of serum-enriched medium. When 80% confluence was reached, 25 ml of 100 nM siRNA in cytofectin was added drop wise. Numbers of viable cells were evaluated after 48 h culture by incubation with Tetra color one, and numbers obtained were compared with those of controls. After transfection with DDR1 siRNAs, U251 cell counts within 48 h were approximately 40-60% of untreated or control-siRNA-treated cells during this same period of time. *Po0.01 compared with both control groups. (c) For the invasion assays, transfectants were seeded onto Matrigel-coated invasion chambers and incubated for 24 h. Total numbers of cells on the underside of each filter were determined. Invading cells were significantly suppressed by siRNAs against DDR1, as reflected by reduction of mRNA expression. Control, no siRNA treatment; negative control, control siRNA treated. DDR1-#1, DDR1-#2; DDR1 siRNA treated. **Po0.01 compared with both control groups.
cell-matrix adhesions, is critical to the maintenance of structural integrity, polarity and cell-cell communication, and their expression is frequently observed in tumor cells concordant with a breakdown of cellular organization, causing an uncontrolled leakage of nutrients and other factors necessary for the survival and growth of tumor cells, and loss of cell-cell contact inhibition leading to increased cell motility. Thus, DDR1 may be a novel molecular target for therapy, and provide an important predictive marker for survival in patients with glioma. KSP37 protein is constitutively secreted by Th1-type CD4-positive lymphocytes and lymphocytes with cytotoxic potential, and may be involved in an essential process of cytotoxic lymphocyte-mediated immunity (Ogawa et al., 2001) . Downregulation of KSP37 protein may correlate with poor prognosis of glioma patients with immunosuppressive state. DYRK3 is a member of dual-specificity tyrosineregulated kinases with roles in cell growth and development. DYRK3 was reported to be expressed in erythroid progenitor cells, and to play roles in kinase activation (Li et al., 2002) . Although KSP37 and DYRK3 are unique molecules, their roles in glioma progression are unclear, and should be further investigated in the future. Regardless of their roles in tumorigenesis, all these markers offer potential clinical applications for the treatment and detection of malignant gliomas. To our knowledge, this study is the first to address these molecules as molecular targets for therapeutics. Values of gene-expression-based predictors for prognosis of malignant glioma patients will not be fully realized until additional therapies are available for patients destined to have poor survival, following conventional chemotherapy. In this regard, expression profiles may not only predict the likelihood of long-term survival following nitrosourea chemotherapy, but may also yield clues on individual genes involved in tumor development, progression and response to therapy. It is likely that some of the most differentially expressed genes such as those discussed above will represent therapeutic molecular targets. Moreover, the ability to histologically distinguish ambiguous gliomas will enable appropriate therapies to be tailored to specific tumor subtypes. Class prediction models based on defined molecular profiles allow classification of malignant gliomas in a manner that will better correlate with clinical outcomes than with standard pathology.
Materials and methods
Patients
Mean age of patients was 53.2 years old (range, 18-80). Twenty-two patients were men and seven were women. Tissues were snap-frozen in liquid nitrogen within 5 min of harvesting, and stored thereafter at À801C. Clinical stage was estimated from accompanying surgical pathology and clinical reports. Samples were specifically re-reviewed by a board-certified pathologist in our institution, using observation of sections of paraffin-embedded tissues that were adjacent or in close proximity to the frozen sample from which the RNA was extracted. Histopathology of each collected specimen was reviewed to confirm adequacy of the sample (i.e., minimal contamination with non-neoplastic elements), and to assess the extent of tumoral necrosis and cellularity. Histological characteristics of tumor samples and clinical disease stage were included as supplements in Table 1 .
After surgical resection of tumor, patients had a course of external beam radiation therapy (standard dose of 40 Gy to the tumor with a 3-cm margin, and 20 Gy boost to the whole brain) and nitrosourea-based chemotherapy. Patients were monitored for recurrences of tumor during the initial and maintenance therapy by magnetic resonance imaging or computed tomography. Treatments were carried out at the Department of Neurosurgery, Niigata University Hospital. Informed consent was obtained from all patients for the use of samples in accordance with the guidelines of the Ethical Committee on Human Research, Niigata University Medical School. Overall survival was measured from the date of diagnosis. Survival end points corresponded to dates of death or last follow-up.
RNA extraction
Total RNA was extracted with 1 ml Isogen (Nippongene, Toyama, Japan) per 100 mg frozen glioma tissues, following the manufacturer's instructions. Each tissue type was homogenized with a Polytron (Fisher Scientific) for 30 s and cleared by a 10-min centrifugation at 10 000 g. For each ml Isogen, 0.2 ml chloroform was added and samples were vigorously shaken for 20 s and then incubated on ice for 10 min. The aqueous phase was separated by centrifugation at 10 000 g for 10 min, decanted and an equal volume of isopropanol was added. The mixture was allowed to precipitate for 10 min and the precipitate was collected by centrifugation at 12 000 g for 10 min. The pellet was washed with 70% ethanol, collected by brief centrifugation, air dried and re-suspended in H 2 O. RNA was further purified using an RNeasy column (Qiagen, Valencia, CA, USA). The purified RNA was quantified using a UV spectrophotometer, and RNA quality was evaluated by capillary electrophoresis on an Agilent 2100 Bioanalyzer (Agilent Technologies). Only samples with 28S/18S ratios >0.7 and with no evidence of ribosomal peak degradation were included in the study.
Agilent cDNA microarrays Agilent human 1 cDNA microarrays (Agilent Technologies) contained 13 156 clones from Incyte's human cDNA library. Test and normal brain RNAs were labeled with both Cy3-dCTP and Cy5-dCTP nucleotides (Amersham Biosciences, Tokyo, Japan) and hybridized on two slides (dye-swap hybridizations) according to the direct-labeling method provided by the manufacturer. Following hybridization, slides were scanned and analysed using the Feature Extraction software (version A.4.0.45, Agilent Technologies), as recommended by the manufacturer. Spots that did not pass quality control procedures in the Feature Extraction software were flagged and removed from further analysis. Clones with the same GenBank accession number were averaged.
Expression profiling on Agilent cDNA microarrays Total RNA (20 mg) was reverse transcribed using the Agilent direct-label cDNA synthesis kit (Agilent Technologies), following the manufacturer's directions. Labeled cDNA was purified using QIAquick PCR Purification columns (Qiagen, Valencia, CA, USA), followed by concentration by vacuum centrifugation. cDNA was suspended in hybridization buffer and hybridized to Agilent human 1 cDNA microarrays (Agilent Technologies) for 17 h at 651C, according to the Agilent protocol. To avoid generation of false between-group differences by randomly pairing glioma samples on the twochannel cDNA arrays, each sample was individually labeled and co-hybridized with a normal brain sample labeled with a complementary dye. Normal brain samples were generated by pooling equal amounts of RNA from each control sample and labeling as for individual samples. In addition, Cy dye switch hybridizations were performed for each sample. Normal brain samples were purchased from Clontech (Tokyo, Japan). All microarray data and clinical features have been submitted to Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih. gov/geo; accession no. GSE4381).
Statistical analysis
Univariate analysis for clinical features was performed by logrank test using SAS software ver. 9.1.3 (SAS Institute Inc., Cary, NC, USA). In microarray analysis, normalization and survival analysis were performed using the BRB Array Tools software ver. 3.3.0 (http://linus.nci.nih.gov/BRB-ArrayTools.html) developed by Dr Richard Simon and Amy Peng. In brief, a log base 2 transformation was applied to the microarray raw data, and global normalization was used to median the center of log ratios on each array in order to adjust for differences in labeling intensities of the Cy3 and Cy5 dyes. Genes showing minimal variation across the set of arrays were excluded from the analysis. Genes whose expression differed by at least 1.5-fold from the median in at least 20% of the arrays were retained. Genes were also excluded if percent of data missing or filtered out exceeds 50%. Then, genes that passed filtering criteria were considered for further analysis. We computed a statistical significance level for each gene based on univariate proportional hazards models (Po0.005) and identified genes whose expression was significantly related to survival of the patient. These P-values were then used in a multivariate permutation test in which survival times and censoring indicators were randomly permuted among arrays. To adjust the expression of six candidate genes (DDR1, DYRK3, KSP37, ITGA5, SLN and ALCAM) for clinical features (WHO grade, age, gender, PS) , clinical data and normalized microarray expression data of six genes were imported into SAS software ver. 9.1.3 (SAS Institute Inc.) and Cox regression model was performed for multivariate analysis against each variable (WHO grade, age, gender, PS, expression levels of six genes). Three samples were excluded for multivariate analysis because there were a few defected expression data. A P-value o0.05 was considered significant. The differences between subgroups of DDR1 siRNA and control groups were tested for statistical significance using the analysis of variance test and statistical significance was determined at the Po0.01 level.
Validation of differential expression by real-time quantitative PCR
Total RNA (2 mg) was subjected to DNase treatment in a 10 ml reaction containing 1 ml 10 Â DNase I reaction buffer (Invitrogen, Tokyo, Japan) and 1 mg DNase I at room temperature for 10 min. Ethylenediamine tetraacetic acid (1 ml, 25 mM) and 1 ml oligo dT (0.5 mg/ml; Invitrogen) were added to the DNase reaction, and heated to 701C for 15 min to inactivate DNase I activity and eliminate RNA secondary structure. Samples were placed on ice for 2 min and collected by brief centrifugation. RNA was then reverse-transcribed into cDNA by adding 8 ml master mix containing 4 ml of 5 Â first strand buffer, 2 ml dithiothreitol (0.1 M), 1 ml dNTPs (10 mM each) and 1 ml SuperScript II (200 U/ml) (Invitrogen), followed by incubation at 421C for 45 min. The reaction was diluted 10-fold with dH 2 O and stored at 41C.
Each sample was subjected to 40 cycles of real-time PCR with a LightCycler (Idaho Technology, Salt Lake City, UT, USA). PCR reagents contained 1 Â LightCycler DNA Master SYBR Green I (Roche Molecular Biochemicals, Mannheim, Germany), 0.5 mM of each primer, 3 mM MgCl 2 and 2 ml cDNA template. PCR conditions were as follows: one cycle of denaturing at 951C for 10 min, followed by 40 cycles of 951C for 15 s, 551C for 5 s and 721C for 10 s. A melting curve was obtained at the end of amplification cycles to verify specificity of the PCR products. Points at which signal fluorescence exceeded background, for each sample and for each gene, were compared to a standard curve generated by four, 10-fold serial dilutions of concentrated cDNA control of each sample subjected to real-time analysis to determine an expression value. All determinations were performed in duplicate. A Student's t-test was conducted to analyse expression values for long-and short-term survivors to determine statistical significance. For amplification of target genes, the following primers were used (Takara, Yotsukaichi, Japan):
Immunohistochemistry Sections (5 mm) from formalin-fixed, paraffin-embedded tissue specimens were deparaffinized in xylene and dehydrated in a graded series of ethanol, followed by a phosphate-buffered saline (PBS) wash. Antigen retrieval was carried out by incubation at 1211C for 10 min in 10 mM sodium citrate (pH 6.0), followed by incubation with 0.3% H 2 O 2 to quench endogenous peroxidase activity. Slides were blocked in 10% normal serum and incubated with rabbit polyclonal anti-DDR1 antibody (dilution 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 16 h at 41C. After washing, the slides were incubated with an avidin-biotin-peroxidase system (Vectastain elite ABC kit, Vector Labs, Burlingame, CA, USA). Finally, sections were exposed for 10-20 min to 0.01% 3,3-diaminobenzidine (Sigma, Tokyo, Japan) and PBS containing 0.01% hydrogen peroxide. Immunohistochemistry scoring was performed as follows. Staining intensity was classified as none (0 point), weak (1 point), moderate (2 point) or strong (3 point). Intensity of signal of stained areas was estimated by light microscopy, based on 25 percentiles in a representative field. Scores were calculated as weighted averages (sum of points Â area%). Averages of three independent measurements were calculated to the first decimal place and used for statistical analysis. Observers were not aware of case numbers.
siRNA treatment and cell proliferation assay Specific siRNA oligonucleotides directed against human DDR1 were purchased from Invitrogen. The Validated Stealth sequence information is DDR1-#1: 5 0 -GCUAUGUGGAGAU GGAGUUUGAGUU-3 0 and DDR1-#2: 5 0 -GGCCCUGG UUACUCUUCAGCGAAAU-3 0 . siRNAs were introduced into glioma cell lines by cytofectin-mediated transfection according to the manufacturer's instructions (Qiagen, Tokyo, Japan). Cells were cultured in 96-well plates in 100 ml of serumenriched medium. When 80% confluence was reached, 25 ml 100 nM siRNA in cytofectin was added drop wise to the cell culture. Numbers of viable cells were evaluated 48 h after culture, by incubating with Tetra color one (Seikagaku CO., Tokyo, Japan), and numbers obtained were compared with those of controls. Control experiments were performed using Cy3-labeled siRNA (Qiagen) directed against an unrelated mRNA (Luciferase; siRNA LUC : Qiagen). Transfection efficiency was confirmed with Cy3-labeled siRNA LUC in each assay. All proliferation experiments were repeated as independent experiments at least twice. Results were reported as means7s.d. of two independent experiments.
Cell invasion of Matrigel
A Transwell containing an 8-mm diameter pore membrane (Becton-Dickinson, Tokyo, Japan) was coated with 500 ml Matrigel (Becton-Dickinson) at 100 mg/ml. Cells were either left untreated, treated with control or DDR1-#1, #2 siRNAs and transfected as described above. After 24-h incubation, cells were detached with cell dissociation solution (Sigma), washed twice with PBS and resuspended in minimum essential medium (MEM) (Nissui Pharmaceutical Inc., Tokyo, Japan) containing 10% fetal bovine serum (FBS) (Gibco, Tokyo, Japan). When siRNAs were used, a second transfection 24 h after the first was performed. In all cases, 2 Â 10 5 cells were seeded into the upper, Matrigel-coated chamber of the Transwell. The lower chamber was filled with MEM supplemented with 10% FBS. After 24-h incubation at 371C, the non-migrating cells in the upper chamber were gently detached by scraping and adherent cells present on the lower surface of each insert were stained with Giemsa. Ten fields were counted by light microscopy at Â 200 magnification. Results were calculated with reference to control values observed after incubation of untreated control, for control and DDR1 siRNA.
Cell lines and culture
All glioma cell lines were cultured in MEM supplemented with 10% FBS. The T98G, GI-1 and U251 cell lines were purchased from Cell Bank, RIKEN BioResource Center (Tsukuba, Japan).
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